PAVmed stock soars as Lucid Diagnostics announces a new VA contract. But owning PAVM shares in 2026 remains a super risky ...
Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback